<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Drugs Made In America Acquisition Corp. Units — News on 6ix</title>
    <link>https://6ix.com/company/drugs-made-in-america-acquisition-corp-units</link>
    <description>Latest news and press releases for Drugs Made In America Acquisition Corp. Units on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 24 Feb 2025 14:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/drugs-made-in-america-acquisition-corp-units" rel="self" type="application/rss+xml" />
    <item>
      <title>Drugs Made in America Acquisition Corp. Announces Advisory Team</title>
      <link>https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-america-acquisition-corp-143000669</link>
      <guid isPermaLink="true">https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-america-acquisition-corp-143000669</guid>
      <pubDate>Mon, 24 Feb 2025 14:30:00 GMT</pubDate>
      <description>Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”. Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactivel</description>
    </item>
    <item>
      <title>Drugs Made In America Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing February 25, 2025</title>
      <link>https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-america-acquisition-corp-213000021</link>
      <guid isPermaLink="true">https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-america-acquisition-corp-213000021</guid>
      <pubDate>Thu, 20 Feb 2025 21:30:00 GMT</pubDate>
      <description>Fort Lauderdale, Florida, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that, commencing February 25, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares and rights included in the units. No fractional rights will be issued upon separation of the units and only whole rights will trade. The ordinary shares and rights that are separated will t</description>
    </item>
    <item>
      <title>Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option</title>
      <link>https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-america-acquisition-corp-214500540</link>
      <guid isPermaLink="true">https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-america-acquisition-corp-214500540</guid>
      <pubDate>Tue, 18 Feb 2025 21:45:00 GMT</pubDate>
      <description>Fort Lauderdale, Florida, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that the underwriter of its previously announced initial public offering fully exercised its option to purchase an additional 3,000,000 units at the public offering price of $10.00 per unit, resulting in additional gross proceeds of $30,000,000. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “DMAAU” on January</description>
    </item>
    <item>
      <title>Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering</title>
      <link>https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-in-america-acquisition-corp-announces-closing-of-dollar200000000-initial-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-in-america-acquisition-corp-announces-closing-of-dollar200000000-initial-public-offering</guid>
      <pubDate>Wed, 29 Jan 2025 05:00:00 GMT</pubDate>
      <description>Fort Lauderdale, FL, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced that it closed</description>
    </item>
    <item>
      <title>Drugs Made In America Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering</title>
      <link>https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-in-america-acquisition-corp-announces-pricing-of-dollar200000000-initial-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/drugs-made-in-america-acquisition-corp-units/news/drugs-made-in-america-acquisition-corp-announces-pricing-of-dollar200000000-initial-public-offering</guid>
      <pubDate>Mon, 27 Jan 2025 05:00:00 GMT</pubDate>
      <description>Fort Lauderdale, FL , Jan. 27, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) announced today the pricing of</description>
    </item>
  </channel>
</rss>